BA
CSCI

Ballew Advisors’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Ballew Advisors’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-30
Closed -$4K – 455
2018
Q3 		$4K Buy
+30
New +$5.5K ﹤0.01% 372

Other funds holding CSCI

JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ballew Advisors's CSCI Position: Q4 2018 in Review

Ballew Advisors sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q4 2018, closing a stake of 30 shares — an estimated $4K sold.

Ballew Advisors first reported a position in CSCI in Q3 2018 and held it in 1 quarter. The position peaked at $4K in Q3 2018. 24 funds tracked by Wall St. Rank hold CSCI as of Q4 2018.

  • Ballew Advisors reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Ballew Advisors sold 30 COSCIENS Biopharma Inc. Common Stock shares in Q4 2018, an estimated $4K.
  • Ballew Advisors first reported a position in COSCIENS Biopharma Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Ballew Advisors's COSCIENS Biopharma Inc. Common Stock position peaked at $4K in Q3 2018.
  • 24 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.